Re-Evaluations of Zr-DFO Complex Coordination Chemistry for the Estimation of Radiochemical Yields and Chelator-to-Antibody Ratios of


Journal

Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009

Informations de publication

Date de publication:
17 Aug 2021
Historique:
received: 11 07 2021
revised: 06 08 2021
accepted: 14 08 2021
entrez: 27 8 2021
pubmed: 28 8 2021
medline: 7 9 2021
Statut: epublish

Résumé

(1) Background: Deferoxamine B (DFO) is the most widely used chelator for labeling of zirconium-89 (

Identifiants

pubmed: 34443566
pii: molecules26164977
doi: 10.3390/molecules26164977
pmc: PMC8401698
pii:
doi:

Substances chimiques

Antibodies, Monoclonal 0
Chelating Agents 0
Radioisotopes 0
Zirconium C6V6S92N3C
Deferoxamine J06Y7MXW4D
Zirconium-89 NTM296JU95

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

J Inorg Biochem. 2019 Sep;198:110753
pubmed: 31229836
Nucl Med Biol. 2018 Sep - Oct;64-65:1-7
pubmed: 30015090
Dalton Trans. 2018 Oct 7;47(37):13214-13221
pubmed: 30178793
Chem Rev. 2020 Apr 22;120(8):3787-3851
pubmed: 32202104
Chem Rev. 2010 May 12;110(5):2858-902
pubmed: 20415480
Front Pharmacol. 2016 May 24;7:131
pubmed: 27252651
Inorg Chem. 2020 Dec 7;59(23):17443-17452
pubmed: 33183002
J Inorg Biochem. 1999 May 30;75(1):27-35
pubmed: 10402674
Inorg Chem. 2017 Feb 6;56(3):1264-1272
pubmed: 28118016
Bioconjug Chem. 2009 May 20;20(5):825-41
pubmed: 19125647
Nucl Med Biol. 2009 Oct;36(7):729-39
pubmed: 19720285
Int J Rad Appl Instrum A. 1992 Dec;43(12):1443-7
pubmed: 1334954
Molecules. 2019 Jun 02;24(11):
pubmed: 31159506
J Nucl Med. 2009 Jan;50(1):2-5
pubmed: 19091888
Bioconjug Chem. 2021 Jul 21;32(7):1177-1191
pubmed: 32197571
Eur J Nucl Med Mol Imaging. 2010 Feb;37(2):250-9
pubmed: 19763566
Oncologist. 2007 Dec;12(12):1379-89
pubmed: 18165614
Nat Protoc. 2010 Apr;5(4):739-43
pubmed: 20360768
Nucl Med Biol. 2007 Oct;34(7):757-78
pubmed: 17921028

Auteurs

Ryota Imura (R)

Research Center for Advanced Science and Technology, The University of Tokyo, 4-6-1 Komaba, Meguro-ku, Tokyo 153-8904, Japan.
JFE Engineering Corporation, 2-1 Suehiro-cho, Tsurumi-ku, Yokohama 230-8611, Japan.

Hiroyuki Ida (H)

JFE Engineering Corporation, 2-1 Suehiro-cho, Tsurumi-ku, Yokohama 230-8611, Japan.

Ichiro Sasaki (I)

Department of Radiation-Applied Biology Research, Takasaki Advanced Radiation Research Institute, National Institute of Quantum and Radiological Science and Technology (QST), 1233 Watanuki, Takasaki, Gunma 370-1292, Japan.

Noriko S Ishioka (NS)

Department of Radiation-Applied Biology Research, Takasaki Advanced Radiation Research Institute, National Institute of Quantum and Radiological Science and Technology (QST), 1233 Watanuki, Takasaki, Gunma 370-1292, Japan.

Shigeki Watanabe (S)

Department of Radiation-Applied Biology Research, Takasaki Advanced Radiation Research Institute, National Institute of Quantum and Radiological Science and Technology (QST), 1233 Watanuki, Takasaki, Gunma 370-1292, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH